《大行報告》中金:內地推進「互聯網+」醫保解決疫情下就醫需求 探索定點藥店配藥直接結算
就國家醫保局、國家衛健委聯合發布《關於推進新冠肺炎疫情防控期間開展「互聯網+」醫保服務的指導意見》,解決疫情期間參保人員就醫購藥需求,中金發表報告表示,疫情期間,各地不斷出現非新冠患者基本就醫需求不能及時得到滿足的現像,催生「醫+藥+險」全鏈路在線化需求,多地及時針對當地患者推出「互聯網+」醫保服務方案,指此次文件的發布,將在全國範圍內推進將「互聯網+」醫療服務費用納入醫保支付範圍,並鼓勵定點醫藥機構提供「不見面」購藥服務。 該行指,今次措施是探索推進定點零售藥店配藥直接結算,料處方外流有望加速。文件指出,落實「長處方」的醫保報銷政策,積極保障高血壓、糖尿病門診用藥需求,患者可憑定點醫療機構在線開具的處方在定點零售藥店配藥。同時,文件鼓勵推進定點零售藥店配藥按照統籌地區規定的醫保政策和標準,分別由個人和醫保基金進行結算,該行認為,若進一步實現定點藥店統籌賬戶直接結算,有利於處方加速外流。 此次文件進一步推進「互聯網+醫療健康」的發展;但中金認為從患者痛點是否真正解決上看,以下幾點仍值得關注,第一是「互聯網+醫」文件要求服務主體是當地符合條件的定點醫療機構,需關注各省市在互聯網醫院建設上的速度,目前仍有諸多省市進展較慢;第二是「互聯網+藥」文件鼓勵探索推進定點零售藥店配藥,需關注各省市定點藥店與處方流轉平台、醫保對接的進度,目前仍有諸多藥店信息化程度不足;第三是「互聯網+險」文件鼓勵使用醫保電子憑證實現互聯網醫保服務無卡辦理,但目前仍然有大量省市不具備開通條件,需關注電子憑證的推廣應用進度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.